■复发性卵巢癌(ROC)预后不佳,持续缺乏有效的治疗策略。在过去的十年里,中华民国管理发生了重大变化,以新型治疗靶标的识别以及生物标志物研究和创新的进步为标志。由于文献计量学是揭示科学文献的有效方法,我们对与ROC有关的文献进行了文献计量分析。我们的探索包括确定新兴的研究趋势和共同的模式,分析协作网络,并在这种临床背景下预测未来的方向。
■我们在WebofScienceCoreCollection(WoSCC)中进行了搜索,以获取相关文章作为我们的数据集,然后使用R-Studio-2023.12.0-369软件导出。BibliometrixR软件包用于对国家/地区进行视觉分析,机构,期刊,作者,具有里程碑意义的文章,和这个研究领域的关键词。
■最终检索了2014年至2023年之间发表的1538篇文章和173篇评论。科学生产的年增长率为4.27%。美国在出版作品数量上领先,总引用次数,和合作。妇科肿瘤学是该研究领域最受青睐的期刊。鲁汶大学医院的VergoteI,是最具影响力的作家。最后,最突出的关键词是“化疗”(n=124),“贝伐单抗”(n=87),和“生存”(n=65)。临床结果(预后,生存),化疗,贝伐单抗,和PARP抑制剂(奥拉帕尼,niraparib)代表了基本和横向主题,而抗体-药物偶联物(ADC)和耐药性是新兴的主题。细胞减少外科手术和他莫昔芬是利基主题,而免疫疗法和生物标志物是运动主题,并且具有很高的中心性。
■通过文献计量分析揭示了过去十年ROC研究领域的趋势。铂电阻,ADC,和免疫疗法已成为当前突出的研究课题。
UNASSIGNED: Recurrent ovarian cancer (ROC) presents a dismal prognosis, persistently devoid of efficacious therapeutic strategies. Over the past decade, significant shifts have transpired in ROC management, marked by the identification of novel therapeutic targets and advancements in biomarker research and innovation. Since bibliometrics is an effective method for revealing scientific literature, we conducted a bibliometric analysis of literature pertaining to ROC. Our exploration encompassed identifying emerging research trends and common patterns, analyzing collaborative networks, and anticipating future directions within this clinical context.
UNASSIGNED: We conducted a search in the Web of Science Core Collection (WoSCC) to acquire relevant articles as our dataset, which were then exported using R-Studio-2023.12.0-369 software. The Bibliometrix R package was utilized to perform visual analyses on countries, institutions, journals, authors, landmark articles, and keywords within this research field.
UNASSIGNED: A total of 1538 articles and 173 reviews published between 2014 and 2023 were eventually retrieved. The annual growth rate of scientific production was 4.27%. The USA led the way in the number of published works, total citations, and collaboration. Gynecologic Oncology was the most favoured journal in this research field. Vergote I from the University Hospital Leuven, was the most influential author. At last, the most prominent keywords were \"chemotherapy\" (n = 124), \"bevacizumab\" (n = 87), and \"survival\" (n = 65). Clinical outcomes (prognosis, survival), chemotherapy, bevacizumab, and PARP inhibitors (olaparib, niraparib) represented the basic and transversal themes, while antibody-drug conjugate (ADC) and drug resistance were emerging themes. Cytoreduction surgical procedures and tamoxifen were niche themes, while immunotherapy and biomarkers were motor themes and had high centrality.
UNASSIGNED: The trends in the ROC research field over the past decade were revealed through bibliometric analysis. Platinum resistance, ADC, and immunotherapy have emerged as the current prominent research topics.